The reality of LAMAs for adult asthmatic patients

References

• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2020. [cited 2019 Oct 10]. Available from: www.ginasthma.com
   Google Scholar
• Dharmage S, Perret J, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7. DOI:10.3389/fped.2019.00246
   PubMed Web of Science ®Google Scholar
• Selroos O, Kupczyk M, Kuna P, et al. National and regional asthma programmes in Europe. Eur Respir Rev. 2015;24:474–483.
   PubMed Web of Science ®Google Scholar
• Sá-Sousa A, Fonseca J, Pereira A, et al. The Portuguese severe asthma registry: development, features, and data sharing policies. Biomed Res Int. 2018;2018:1–12.
   Web of Science ®Google Scholar
• Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and Link to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24. DOI:10.1038/npjpcrm.2014.9
   Web of Science ®Google Scholar
• Boehringer ingelheim pharmaceuticals I summary of product characteristics labelling and package leaflet. 208. [cited 2020 Jan 9]. Available from: http://mri.cts-mrp.eu/download/NL_H_0299_001_FinalPI.pdf
   Google Scholar
• National Institute for Health and Care Excellence. ESNM55: asthma: tiotropium (Spiriva Respimat) [online]. 2015 [cited 2020 Jan 10]. Available from: http://www.nice.org.uk/advice/esnm
   Google Scholar
• Sobieraj D, Baker W, Nguyen E, et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma. JAMA. 2018;319(14):1473.
   PubMed Web of Science ®Google Scholar
• Lewis M, Short A, Lewis K. Autonomic nervous system control of the cardiovascular and respiratory systems in asthma. Respir Med. 2006;100:1688–1705.
   PubMed Web of Science ®Google Scholar
• Ferrando M, Bagnasco D, Braido F, et al. Umeclidinium for the treatment of uncontrolled asthma. Expert Opin Investig Drugs. 2017;26:761–766.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ora J, Rogliani P, et al. Role of muscarinic antagonists in asthma therapy. Expert Rev Respir Med. 2017;11:239–253. .
   PubMed Web of Science ®Google Scholar
• Scott G, Fryer A. Role of parasympathetic nerves and muscarinic receptors in allergy and asthma. Chem Immunol Allergy. 2012;48–69. DOI:10.1159/000336498
   PubMedGoogle Scholar
• Rogers DF. Motor control of airway goblet cells and glands. Respir Physiol. 2001;125:129–144.
   PubMedGoogle Scholar
• Rogers L, Hanania N. Role of anticholinergics in asthma management. Curr Opin Pulm Med. 2015;21:103–108.
   PubMed Web of Science ®Google Scholar
• Mansfield L, Bernstein J. Tiotropium in asthma: from bench to bedside. Respir Med. 2019;154:47–55.
   PubMed Web of Science ®Google Scholar
• Gosens R, Gross N. The mode of action of anticholinergics in asthma. Eur Respir J. 2018;52:1701247.
   PubMed Web of Science ®Google Scholar
• Chari V, McIvor R. Tiotropium for the treatment of asthma: patient selection and perspectives. Can Respir J. 2018;2018:1–10. .
   Web of Science ®Google Scholar
• Lipworth B. Emerging role of long acting muscarinic antagonists for asthma. Br J Clin Pharmacol. 2013;77:55–62.
   Web of Science ®Google Scholar
• Boehringer Ingelheim Limited. Spiriva Respimat 2.5 microgram inhalation solution. [cited 2020 Jan 9]. Available from: http://www.medicines.org.uk/emc/medicine/20134/SPC
   Google Scholar
• U.S. Food and Drug Administration. Prescribing information for Spiriva® Respimat® (tiotropium bromide) inhalation spray, for oral inhalation. 2017 [cited 2020 Mar 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021936s007lbl.pdf
   Google Scholar
• Quirce S, Dominguez-Ortega J, Barranco P. Anticholinergics for treatment of asthma. J Investig Allergol Clin Immunol. 2015;25:84–93.
   PubMed Web of Science ®Google Scholar
• Haney S, Hancox RJ. Recovery from bronchoconstriction and bronchodilator tolerance. Clin Rev Allergy Immunol. 2006;31:181–196.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur J Pharmacol. 2015 Aug 15;761:168–173. Epub 2015 May 14. .
   PubMed Web of Science ®Google Scholar
• Halpin DM, Kaplan AG, Russell RK. Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators. Respir Med. 2017;128:28–41.
   PubMed Web of Science ®Google Scholar
• Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide stepup therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363:1715–1726.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Casale TB, Bleecker ER, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, doubleblind, placebo-controlled, parallel-group, active-comparator, randomized trials. Lancet Respir Med. 2015;3:367–376.
   PubMed Web of Science ®Google Scholar
• Paggiaro P, Halpin DM, Buhl R, et al. The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trial. J Allergy Clin Immunol Pract. 2016;4:104–113.e2.
   PubMed Web of Science ®Google Scholar
• Fardon T, Haggart K, Lee D, et al. A proof of concept study to evaluate stepping down the dose of fluticasone in the combination with salmeterol and tiotropium in severe persistent asthma. Respir Med. 2007;101:1218–1228.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Disse B, Schröder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol. 2007;128:308–314.
   Google Scholar
• Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367:1198–1207.
   PubMed Web of Science ®Google Scholar
• Abadoglu O, Berk S. Tiotropium may improve asthma symptoms and lung function in asthmatic patients with irreversible airway obstruction: the reallife data. Clin Respir J. 2016;10(4):421–427.
   PubMed Web of Science ®Google Scholar
• Slater M, Pavord I, Step SD. 4: stick or twist? A review of asthma therapy. BMJ Open Respir Res. 2016;3:e000143.
   PubMed Web of Science ®Google Scholar
• Chung K, Wenzel S, Brozek J, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2013;43:343–373.
   PubMed Web of Science ®Google Scholar
• Rhee C, Yoshisue H, Lad R. Fixed-dose combinations of long-acting bronchodilators for the management of COPD: global and Asian perspectives. Adv Ther. 2019;36:495–519.
   PubMed Web of Science ®Google Scholar
• Lee L, Yang S, Kerwin E, et al. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study. Respir Med. 2015;54–62. DOI:10.1016/j.rmed.2014.09.012
   PubMedGoogle Scholar
• Lazarus S, Krishnan J, King T, et al. Mometasone or tiotropium in mild asthma with a low sputum eosinophil level. N Engl J Med. 2015;380(21):2009–2019.
   Google Scholar
• Ciprandi G, Tosca M, Silvestri M, et al. Inflammatory biomarkers for asthma endotyping and consequent personalized therapy. Expert Rev Clin Immunol. 2017;13(7):715–721.
   PubMed Web of Science ®Google Scholar
• Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161–175. .
   PubMed Web of Science ®Google Scholar
• Casale TB, Bateman ED, Aalbers R, et al. Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics. Eur Respir J. 2017;50:PA647.
   Web of Science ®Google Scholar
• Kerstjens HAM, Moroni-Zentgraf P, Tashkin DP, et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med. 2016;117:198–206.
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217–224.
   PubMed Web of Science ®Google Scholar
• United States national institute of health, clinical trials database. [cited 2019 Oct 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02571777
   Google Scholar
• United States national institute of health, clinical trials database. [cited 2019 Oct 20]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02924688
   Google Scholar
• Paggiaro P, Kuna P, Kots M, et al. Efficacy and safety of a fixed combination extrafine beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/GB) pMDI treatment compared to fixed combination BDP/FF in patients with uncontrolled asthma on medium dose ICS/LABA: the TRIMARAN study. Am J Respir Crit Care Med. 2019;199:A7080.
   Web of Science ®Google Scholar
• Canonica GWW, Virchow JC, Kotz M, et al. Efficacy and safety of high ICS dose fixed combination ICS/LABA/LAMA pMDI compared with ICS/LABA and ICS/LABA + LAMA in patients with uncontrolled asthma: the TRIGGER study. Am J Respir Crit Care Med. 2019;199:7362.
   Web of Science ®Google Scholar
• Virchow JC, Canonica WG, Paggiaro P, et al. Reducing the rate of severe asthma exacerbations using single-inhaler extrafine BDP/FF/GB combination compared to BDP/FF in patients with uncontrolled asthma: pooled results from the TRIMARAN and TRIGGER studies. Am J Respir Crit Care Med. 2019;394(10210):1737–1749.
   Google Scholar
• Chapman D, Irvin C. Mechanisms of airway hyper-responsiveness in asthma: the past, present and yet to come. Clin Exp Allergy. 2015;45:706–719.
   PubMed Web of Science ®Google Scholar
• Bateman E, Rennard S, Barnes P, et al. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther. 2009;22:533–542.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Puxeddu E, et al. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Respir Res. 2016;17(1):70. .
   PubMed Web of Science ®Google Scholar
• Morrison J, Pearson S. The parasympathetic nervous system and the diurnal variation of lung mechanics in asthma. Respir Med. 1991;85:285–289.
   PubMed Web of Science ®Google Scholar
• Casarosa P, Pieper MP, Gantner F. Cross-talk between the human muscarinic M3 and b2 receptors: evidence for heterologous desensitization. Am J Respir Crit Care Med. 2010;181 (abs A6373).
   Web of Science ®Google Scholar